Cytochrome P450 Compound Profiling on the Fluent™ Laboratory Automation Solution

The failure of preclinical drug entities is a major problem for pharmaceutical companies, accounting for substantial proportions of their precious R&D budgets. As a consequence, there is a need to bring compound toxicity testing into a high throughput environment similar to primary efficacy screening. This application note describes a 384-well microplate format lead generation method using three different CYP enzymes, illustrating a typical assay run in an ADME laboratory.